Previous 10 | Next 10 |
BURLINGAME, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on the development of next generation CAR-T and other cell therapies, announced today that it is contemplating conducting a br...
NEW YORK , Oct. 14, 2019 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the October 10 th conference are now available for on-demand viewing at VirtualInvestorConferences.com. RE...
GM-CSF from the donor T cells initiates a cascade that drives lethal GvHD Without GM-CSF signaling, there was a significant reduction in acute GvHD Provide a logical rationale to administer lenzilumab (to neutralize GM-CSF) early after allogeneic transplant to prevent or treat high risk ...
BURLINGAME, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (HGEN) (“Humanigen”) a clinical stage biopharmaceutical company focused on the development of next generation cell and gene therapies using its proprietary granulocyte-macrophage colony stimulating factor...
Live Investor Conference & Webinar: Executives from Small and MicroCap companies present October 10th Live Investor Conference & Webinar: Executives from Small and MicroCap companies present October 10th Canada NewsWire NEW YORK, Oct. 4, 2019 Company executives wi...
Humanigen ( OTCQB:HGEN ) inks an agreement with the University of Zurich (UZH) securing exclusive global rights to technology used to prevent graft versus host disease (GvHD) via granulocyte macrophage-colony stimulating factor (GM-CSF) neutralization. More news on: Humanigen, Inc., Heal...
Expands Humanigen’s extensive intellectual property portfolio to include prevention of Graft-versus-Host Disease (GvHD) Strengthens Humanigen’s leadership position and platform in granulocyte macrophage-colony stimulating factor (GM-CSF) neutralization to include ...
Expands Humanigen’s intellectual property portfolio to include gene-edited CAR-T cells Builds and further strengthens Humanigen’s leadership position in GM-CSF neutralization GM-CSF neutralization has the potential to break the efficacy/toxicity linkage of C...
Expands Humanigen’s intellectual property portfolio to include gene-edited CAR-T cells Builds and further strengthens Humanigen’s leadership position in GM-CSF neutralization GM-CSF neutralization has the potential to break the efficacy/toxicity linkage of C...
BURLINGAME, Calif., June 03, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (HGEN) (“Humanigen”) a biopharmaceutical company focused on the development of its proprietary Humaneered ® monoclonal antibodies focused on chimeric antigen receptor T (CAR-T) cell therapy optimiza...
News, Short Squeeze, Breakout and More Instantly...
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...